305 related articles for article (PubMed ID: 22858101)
21. Intracellular reduction/activation of a disulfide switch in thiosemicarbazone iron chelators.
Akam EA; Chang TM; Astashkin AV; Tomat E
Metallomics; 2014 Oct; 6(10):1905-12. PubMed ID: 25100578
[TBL] [Abstract][Full Text] [Related]
22. Membrane transport and intracellular sequestration of novel thiosemicarbazone chelators for the treatment of cancer.
Merlot AM; Pantarat N; Lovejoy DB; Kalinowski DS; Richardson DR
Mol Pharmacol; 2010 Oct; 78(4):675-84. PubMed ID: 20605952
[TBL] [Abstract][Full Text] [Related]
23. Iron chelators of the dipyridylketone thiosemicarbazone class: precomplexation and transmetalation effects on anticancer activity.
Bernhardt PV; Sharpe PC; Islam M; Lovejoy DB; Kalinowski DS; Richardson DR
J Med Chem; 2009 Jan; 52(2):407-15. PubMed ID: 19090766
[TBL] [Abstract][Full Text] [Related]
24. Targeting cancer by binding iron: Dissecting cellular signaling pathways.
Lui GY; Kovacevic Z; Richardson V; Merlot AM; Kalinowski DS; Richardson DR
Oncotarget; 2015 Aug; 6(22):18748-79. PubMed ID: 26125440
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and antiproliferating activity of iron chelators of hydroxyamino-1,3,5-triazine family.
Sun D; Melman G; Letourneau NJ; Hays AM; Melman A
Bioorg Med Chem Lett; 2010 Jan; 20(2):458-60. PubMed ID: 20005708
[TBL] [Abstract][Full Text] [Related]
26. Structure-activity relationships of novel iron chelators for the treatment of iron overload disease: the methyl pyrazinylketone isonicotinoyl hydrazone series.
Kalinowski DS; Sharpe PC; Bernhardt PV; Richardson DR
J Med Chem; 2008 Jan; 51(2):331-44. PubMed ID: 18159922
[TBL] [Abstract][Full Text] [Related]
27. Iron chelators as anti-neoplastic agents: current developments and promise of the PIH class of chelators.
Lovejoy DB; Richardson DR
Curr Med Chem; 2003 Jun; 10(12):1035-49. PubMed ID: 12678675
[TBL] [Abstract][Full Text] [Related]
28. Identification of the di-pyridyl ketone isonicotinoyl hydrazone (PKIH) analogues as potent iron chelators and anti-tumour agents.
Becker EM; Lovejoy DB; Greer JM; Watts R; Richardson DR
Br J Pharmacol; 2003 Mar; 138(5):819-30. PubMed ID: 12642383
[TBL] [Abstract][Full Text] [Related]
29. Novel thiosemicarbazones of the ApT and DpT series and their copper complexes: identification of pronounced redox activity and characterization of their antitumor activity.
Jansson PJ; Sharpe PC; Bernhardt PV; Richardson DR
J Med Chem; 2010 Aug; 53(15):5759-69. PubMed ID: 20597487
[TBL] [Abstract][Full Text] [Related]
30. Anticancer activity of the thiosemicarbazones that are based on di-2-pyridine ketone and quinoline moiety.
Mrozek-Wilczkiewicz A; Malarz K; Rejmund M; Polanski J; Musiol R
Eur J Med Chem; 2019 Jun; 171():180-194. PubMed ID: 30921758
[TBL] [Abstract][Full Text] [Related]
31. The potent and novel thiosemicarbazone chelators di-2-pyridylketone-4,4-dimethyl-3-thiosemicarbazone and 2-benzoylpyridine-4,4-dimethyl-3-thiosemicarbazone affect crucial thiol systems required for ribonucleotide reductase activity.
Yu Y; Suryo Rahmanto Y; Hawkins CL; Richardson DR
Mol Pharmacol; 2011 Jun; 79(6):921-31. PubMed ID: 21389104
[TBL] [Abstract][Full Text] [Related]
32. Methyl and ethyl ketone analogs of salicylaldehyde isonicotinoyl hydrazone: novel iron chelators with selective antiproliferative action.
Macková E; Hrušková K; Bendová P; Vávrová A; Jansová H; Hašková P; Kovaříková P; Vávrová K; Simůnek T
Chem Biol Interact; 2012 May; 197(2-3):69-79. PubMed ID: 22521999
[TBL] [Abstract][Full Text] [Related]
33. Iron chelators for the treatment of cancer.
Yu Y; Gutierrez E; Kovacevic Z; Saletta F; Obeidy P; Suryo Rahmanto Y; Richardson DR
Curr Med Chem; 2012; 19(17):2689-702. PubMed ID: 22455580
[TBL] [Abstract][Full Text] [Related]
34. The medicinal chemistry of novel iron chelators for the treatment of cancer.
Kovacevic Z; Kalinowski DS; Lovejoy DB; Yu Y; Suryo Rahmanto Y; Sharpe PC; Bernhardt PV; Richardson DR
Curr Top Med Chem; 2011; 11(5):483-99. PubMed ID: 21192781
[TBL] [Abstract][Full Text] [Related]
35. Heterocyclic dithiocarbazate iron chelators: Fe coordination chemistry and biological activity.
Basha MT; Chartres JD; Pantarat N; Ali MA; Mirza AH; Kalinowski DS; Richardson DR; Bernhardt PV
Dalton Trans; 2012 Jun; 41(21):6536-48. PubMed ID: 22362375
[TBL] [Abstract][Full Text] [Related]
36. Iron chelators as therapeutic agents for the treatment of cancer.
Richardson DR
Crit Rev Oncol Hematol; 2002 Jun; 42(3):267-81. PubMed ID: 12050019
[TBL] [Abstract][Full Text] [Related]
37. Novel thiosemicarbazone iron chelators induce up-regulation and phosphorylation of the metastasis suppressor N-myc down-stream regulated gene 1: a new strategy for the treatment of pancreatic cancer.
Kovacevic Z; Chikhani S; Lovejoy DB; Richardson DR
Mol Pharmacol; 2011 Oct; 80(4):598-609. PubMed ID: 21719465
[TBL] [Abstract][Full Text] [Related]
38. Quantitative analysis of the anti-proliferative activity of combinations of selected iron-chelating agents and clinically used anti-neoplastic drugs.
Potuckova E; Jansova H; Machacek M; Vavrova A; Haskova P; Tichotova L; Richardson V; Kalinowski DS; Richardson DR; Simunek T
PLoS One; 2014; 9(2):e88754. PubMed ID: 24586383
[TBL] [Abstract][Full Text] [Related]
39. Synthesis and antitumor activity of liquiritigenin thiosemicarbazone derivatives.
Hu K; Yang ZH; Pan SS; Xu HJ; Ren J
Eur J Med Chem; 2010 Aug; 45(8):3453-8. PubMed ID: 20494492
[TBL] [Abstract][Full Text] [Related]
40. Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment.
Yuan J; Lovejoy DB; Richardson DR
Blood; 2004 Sep; 104(5):1450-8. PubMed ID: 15150082
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
